🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

3,067 results for “Hospital” Clear

  1. 1 apical pleurectomy

    Hospital Authority, Hong Kong

    Pneumothorax

    phase 3 other active

    1 trial

  2. 2 cycles induction chemotherapy

    The First People's Hospital of Lianyungang

    Locally Advanced Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  3. 20 mg sildenafil citrate by mouth

    The First People's Hospital of Lianyungang

    Pulmonary Hypertension

    phase 3 small molecule active

    1 trial

  4. 2mg Baricitinib

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Ichemic Stroke

    phase 3 small molecule active

    1 trial

  5. 3-N-butylphthalide

    Second Affiliated Hospital, School of Medicine, Zhejiang University

    Multiple System Atrophy

    phase 3 small molecule active

    1 trial

  6. 3-N-butylphthalide

    The First People's Hospital of Lianyungang

    Multiple System Atrophy

    phase 3 small molecule active

    1 trial

  7. 5% Lidocaine patch

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Herpes Zoster Pain

    phase 3 small molecule completed

    1 trial

  8. 5% cysteamine cream

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Melasma

    phase 3 other completed

    1 trial

  9. 5-Fu/epirubicin/CTX following Docetaxel

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Breast Cancer

    phase 3 small molecule active

    1 trial

  10. 6-month course of antiandrogen drugs

    The First People's Hospital of Lianyungang

    Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

    phase 3 small molecule active

    1 trial

  11. 68Ga-PSMA-11

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Biochemical Recurrence of Malignant Neoplasm of Prostate

    phase 3 small molecule active

    1 trial

  12. ABIRATERONE ACETATE, DAROLUTAMIDE, Locametz 25 micrograms kit for radiopharmaceutical preparation, APALUTAMIDE, Pluvicto 1 000 MBq/mL solution for injection/infusion, ENZALUTAMIDE

    Ningbo Cancer Hospital

    Novo metastatic hormone-sensitive prostate cancer (mHSPC) patients having a serum PSA level of ≥ 0.2 ng/mL at 6 to 8 months after systemic treatment initiation for mHSPC (i.e. poor responders) in the absence of evidence of cancer progression (including a rising PSA level)

    phase 3 small molecule active

    1 trial

  13. ALPELISIB, ALPELISIB, ALPELISIB

    Ningbo Cancer Hospital

    PIK3CA mutated HER2+ advanced or relapsed breast cancer (BC) previously treated with trastuzumab

    phase 3 small molecule active

    1 trial

  14. APALUTAMIDE , RELUGOLIX , DAROLUTAMIDE , LEUPRORELIN , GOSERELIN , DEGARELIX , ENZALUTAMIDE , TRIPTORELIN , ABIRATERONE

    Ningbo Cancer Hospital

    Metastatic hormone naïve prostate cancer (mHNPC)

    phase 3 small molecule active

    1 trial

  15. ASC09F+Oseltamivir

    Tongji Hospital

    2019-nCoV Pneumonia

    phase 3 small molecule active

    1 trial

  16. AST-120and pentoxyphylline (PTX)

    Hospital Authority, Hong Kong

    Acute Kidney Injury

    phase 3 small molecule active

    1 trial

  17. ATLG

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hematopoietic Stem Cell Transplantation

    phase 3 small molecule active

    1 trial

  18. AVELUMAB, DOSTARLIMAB, ATEZOLIZUMAB, AVELUMAB, CEMIPLIMAB, DOSTARLIMAB, NIVOLUMAB, PEMBROLIZUMAB, NIVOLUMAB, DURVALUMAB, CEMIPLIMAB, ATEZOLIZUMAB, PEMBROLIZUMAB, DURVALUMAB

    Ningbo Cancer Hospital

    Only patients with oncologic locally advanced or metastatic tumour (lung cancer, renal cell cancer (except IMDC favorable-risk treated Tyrosine Kinase Inhibitor [TKI] / immunotherapy [IO] combination), head and neck cancer, urothelial carcinoma, triple negative breast cancer, Merkel cancer, melanoma, hepatocellular carcinoma, colorectal carcinoma with microsatellite instability [MSI], esophageal squamous cell carcinoma, endometrial carcinoma, or cervical cancer, gastric/gastro-esophageal junction/esophageal adenocarcinoma, basal cell carcinoma or squamous skin carcinoma) in partial or complete response (except for melanoma, only patients in partial response) after 6 months of standard IO treatment (monotherapy or previously in combination with other immunotherapy (ipilimumab) or chemotherapy or continuous combination with pemetrexed or bevacizumab or TKI).

    phase 3 small molecule active

    1 trial

  19. AZVUDINE

    The First People's Hospital of Lianyungang

    Chronic Hepatitis B

    phase 3 small molecule active

    1 trial

  20. Acetazolamide Levamisole

    The First People's Hospital of Lianyungang

    HCC

    phase 3 small molecule active

    1 trial

  21. Adjuvant chemotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Total Neoadjuvant Treatment

    phase 3 small molecule active

    1 trial

  22. Adjuvant immunotherapy

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial

  23. Aerobic Exercise

    The First People's Hospital of Lianyungang

    Primary Hypertension

    phase 3 other active

    1 trial

  24. Afinitor 5 mg tablets, PLACEBO

    Ningbo Cancer Hospital

    Patients with high risk of relapse, ER+ and HER2- primary non-metastatic breast cancer who remain disease-free

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources